Skip to main content

FDA Approvals

Payers' Guide, FDA Approvals

Zejula (Niraparib) First PARP Inhibitor Approved for Maintenance Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Lisa A. Raedler, PhD, RPh

FDA News - August 2017

Novel Assay Provides 100 Times More Information Than Current Liquid Biopsies for Early Cancer Detection

Cediranib-Based Combination Therapy Extends Progression-Free Survival in Relapsed Ovarian Cancer

Dacomitinib Represents Potential New Targeted Therapy for EGFR Mutation–Positive Lung Cancer

Novel Drug “Home Run” for TRK Mutation–Positive Tumors

First FDA-Approved Test to Help Detect Several Leukemias and Lymphomas

First CAR T-Cell Therapy Unanimously Recommended by FDA Advisory Committee for Treatment of B-Cell ALL in Children and Young Adults

FDA Approvals, In the News

Rituximab Combination Now Approved in 3 Blood Cancers

Darzalex Combined with Pomalidomide and Dexamethasone Approved for Relapsed/Refractory Multiple Myeloma

Page 30 of 53
Results 291 - 300 of 524